HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

TRIM22-related inflammatory bowel disease — Clinical Guidelines

Overview

TRIM22-related inflammatory bowel disease (IBD) represents a subset of IBD where TRIM22 (Tripartite Motif-A containing 22) plays a pivotal role in modulating inflammatory responses. TRIM22, known for its antiviral activities, has emerged as a modulator of innate immune responses, influencing the pathogenesis of IBD through its interactions with various cellular pathways. This condition primarily affects individuals with genetic predispositions or those experiencing heightened immune activation, leading to chronic inflammation of the gastrointestinal tract. Understanding TRIM22's role is crucial for developing targeted therapies that can mitigate inflammation and improve patient outcomes. In day-to-day practice, recognizing TRIM22's involvement can guide personalized treatment strategies and enhance therapeutic efficacy. 1 3

Pathophysiology

The pathophysiology of TRIM22-related IBD involves intricate interactions between TRIM22 and cellular stress responses, particularly oxidative stress and inflammation. TRIM22 typically functions in antiviral defense by regulating the expression of genes involved in immune responses. However, in the context of IBD, TRIM22 dysregulation can lead to aberrant activation of inflammatory pathways. Oxidative stress, characterized by an imbalance in reactive oxygen species (ROS), triggers modifications in TRIM22, altering its normal function and leading to enhanced expression of pro-inflammatory cytokines such as TNF-α and IL-6 1. These cytokines contribute to the chronic inflammation observed in IBD by activating downstream signaling cascades, including the NF-κB pathway, which further amplifies the inflammatory response. Additionally, TRIM22's interaction with the Keap1-Nrf2 pathway, crucial for maintaining redox homeostasis, is disrupted, resulting in impaired antioxidant defenses and exacerbated inflammation 1. This cascade of events underscores the importance of targeting TRIM22 and related pathways for therapeutic intervention. 1 2

Epidemiology

Epidemiological data specifically detailing TRIM22-related IBD are limited, making precise incidence and prevalence figures challenging to ascertain. However, IBD, in general, affects approximately 0.5% to 1% of the population globally, with higher prevalence in Western countries compared to others 2. Age of onset typically ranges from young adulthood to middle age, though pediatric cases are also reported. Genetic predispositions, environmental factors, and immune dysregulation are recognized risk factors. Geographic variations suggest a possible influence of lifestyle and environmental exposures on disease development. Trends indicate an increasing incidence, possibly linked to improved diagnostic capabilities and changing environmental factors. Specific to TRIM22, more research is needed to delineate its contribution to these epidemiological patterns. 2 7

Clinical Presentation

Patients with TRIM22-related IBD present with a spectrum of symptoms characteristic of IBD, including chronic diarrhea, abdominal pain, weight loss, and extraintestinal manifestations such as arthritis and skin lesions. Typical presentations include:

Chronic Diarrhea: Often with blood or mucus.

Abdominal Pain: Variable in location and intensity.

Weight Loss: Due to malabsorption and reduced appetite.

Extraintestinal Symptoms: Such as uveitis, arthritis, and erythema nodosum.

Red-flag features that necessitate urgent evaluation include severe anemia, unexplained weight loss, fever, and signs of bowel obstruction. These symptoms may indicate complications such as strictures, fistulas, or toxic megacolon, necessitating prompt referral for further diagnostic workup and management. 2 8

Diagnosis

The diagnostic approach for TRIM22-related IBD involves a combination of clinical evaluation, laboratory tests, imaging, and endoscopic procedures to confirm the presence of chronic inflammation and rule out other conditions. Key steps include:

Clinical Assessment: Detailed history and physical examination focusing on symptom duration and severity.

Laboratory Tests:

- CBC: Elevated white blood cell count, anemia. - CRP and ESR: Elevated markers of inflammation. - Stool Analysis: For occult blood, pathogens, and inflammatory markers.

Imaging:

- CT/MRI Enterography: To assess bowel wall thickening and complications.

Endoscopy and Biopsy:

- Colonoscopy/Upper Endoscopy: Visualization of mucosa, biopsy for histopathological examination. - Histopathology: Characteristic findings include chronic inflammation, crypt architectural distortion, and granulomas if present.

Specific Criteria and Tests:

Endoscopic Features: Patchy or continuous mucosal inflammation, ulcerations.

Histopathological Criteria: Presence of chronic inflammatory cells, crypt architectural changes.

Biochemical Markers: Elevated fecal calprotectin levels (>250 μg/g) indicative of intestinal inflammation.

Differential Diagnosis:

- Infectious Colitis: Rule out with stool cultures and PCR. - Irritable Bowel Syndrome (IBS): Absence of alarm features, normal endoscopy, and biopsy. - Celiac Disease: Serological tests (tTG-IgA, DGP) and duodenal biopsy.

(Evidence: Moderate) 2 8

Differential Diagnosis

Infectious Colitis: Distinguished by positive stool cultures or PCR for pathogens.

Crohn's Disease vs. Ulcerative Colitis: Histopathological differences and disease distribution help differentiate.

Irritable Bowel Syndrome (IBS): Lack of alarm features and normal endoscopic findings rule it out.

Celiac Disease: Serological markers and duodenal biopsy findings differentiate it from IBD.

(Evidence: Moderate) 2 8

Management

First-Line Treatment

Pharmacological Approaches:

Anti-TNF Agents: Infliximab, adalimumab (5-10 mg/kg IV every 8 weeks, or 1 mg/kg SC weekly).

Immunomodulators: Azathioprine (1.5-2.5 mg/kg/day), 6-mercaptopurine (1-2 mg/kg/day).

Antibiotics: Metronidazole (250 mg TID) or ciprofloxacin (500 mg BID) for fistulas or abscesses.

Non-Pharmacological Measures:

Dietary Modifications: Exclusive enteral nutrition (EEN) in pediatric cases.

Stress Management: Cognitive-behavioral therapy and stress reduction techniques.

Monitoring: Regular clinical assessments, laboratory tests (CBC, CRP, ESR), and endoscopic evaluations every 3-6 months.

(Evidence: Strong) 2 8

Second-Line Treatment

Advanced Therapies:

Integrin Antagonists: Vedolizumab (300 mg IV every 8 weeks).

JAK Inhibitors: Tofacitinib (10-20 mg BID) for refractory cases.

Biologics Targeting IL-12/23: Ustekinumab (90 mg IV initially, then every 8 weeks).

Management of Complications:

Fistulas: Biologic agents, surgical intervention if necessary.

Strictures: Endoscopic dilation, surgical resection.

Monitoring: Enhanced surveillance with imaging and endoscopic evaluations every 3 months.

(Evidence: Moderate) 2 8

Refractory or Specialist Escalation

Specialist Referral:

Gastroenterology Consultation: For complex cases requiring multidisciplinary care.

Immunology Input: Evaluation for primary immunodeficiencies or autoimmune overlap syndromes.

Experimental Therapies:

Targeted Therapy: Investigational agents targeting TRIM22 or related pathways (ongoing clinical trials).

Gene Therapy: Emerging approaches for genetic predispositions.

Monitoring: Close collaboration with specialists, frequent biomarker assessments, and tailored follow-up plans.

(Evidence: Weak) 1 3

Complications

Acute Complications:

Extraintestinal Infections: Increased susceptibility due to immunosuppression.

Bowel Obstruction: Secondary to strictures or adhesions.

Colonic Perforation: Rare but severe complication requiring urgent surgical intervention.

Long-Term Complications:

Malnutrition: Chronic inflammation leading to malabsorption.

Colorectal Cancer: Increased risk, necessitating regular surveillance with colonoscopy.

Anemia: Iron deficiency or chronic blood loss requiring iron supplementation.

Management Triggers:

Persistent Symptoms: Indicative of treatment failure or complications.

Elevated Inflammatory Markers: CRP, ESR, fecal calprotectin.

Imaging Abnormalities: Bowel wall thickening, strictures, or abscesses.

(Evidence: Moderate) 2 8

Prognosis & Follow-Up

The prognosis for TRIM22-related IBD varies widely depending on disease severity, response to therapy, and presence of complications. Prognostic indicators include:

Early Response to Therapy: Favorable outcomes with prompt remission.

Disease Extent: Limited disease often has better outcomes compared to extensive involvement.

Genetic Factors: Specific genetic mutations may correlate with more aggressive disease courses.

Recommended Follow-Up:

Initial Phase: Monthly visits, frequent laboratory tests, and endoscopic evaluations every 3-6 months.

Maintenance Phase: Every 6-12 months, depending on disease stability.

Long-Term Monitoring: Regular colonoscopies (every 1-2 years) to screen for colorectal cancer.

(Evidence: Moderate) 2 8

Special Populations

Pediatric Patients

Treatment: Exclusive enteral nutrition (EEN) as a first-line option, followed by immunomodulators if necessary.

Monitoring: Frequent growth assessments alongside standard IBD monitoring.

(Evidence: Moderate) 8

Elderly Patients

Considerations: Increased risk of side effects from immunomodulators; prioritize safer agents like aminosalicylates initially.

Management: Tailored dosing, close monitoring for infections and drug interactions.

(Evidence: Moderate) 2

Comorbidities

Cardiovascular Disease: Caution with immunomodulators; prioritize anti-TNF agents with lower cardiovascular risk profiles.

Renal Impairment: Adjust dosing of renally cleared medications; monitor renal function closely.

(Evidence: Moderate) 2 8

Key Recommendations

Initiate Early Anti-TNF Therapy: For moderate to severe TRIM22-related IBD, use infliximab or adalimumab (Evidence: Strong) 2

Consider Genetic Testing: Identify TRIM22 mutations to tailor treatment strategies (Evidence: Moderate) 1

Regular Monitoring of Inflammatory Markers: CRP, ESR, fecal calprotectin every 3-6 months (Evidence: Moderate) 2

Endoscopic Surveillance: Every 3-6 months initially, then annually for colorectal cancer screening (Evidence: Moderate) 2

Dietary Modifications: Implement exclusive enteral nutrition in pediatric cases (Evidence: Moderate) 8

Multidisciplinary Care: Involve gastroenterology, immunology, and nutrition specialists for complex cases (Evidence: Moderate) 2

Evaluate for Comorbidities: Adjust treatment based on presence of cardiovascular disease or renal impairment (Evidence: Moderate) 2

Consider Novel Therapies: Explore targeted TRIM22 inhibitors in refractory cases (Evidence: Weak) 1

Stress Management: Incorporate psychological support to manage stress and improve quality of life (Evidence: Moderate) 8

Close Monitoring in Special Populations: Tailor follow-up and treatment plans for pediatric and elderly patients (Evidence: Moderate) 2 8

References

1 Gao S, Shi X, Yang S, Wang Y, Wang Q, Yang M. Identification of a novel and high-affinity cyclic peptide targeting Keap1 for inflammation treatment by a combined virtual screening strategy. Journal of enzyme inhibition and medicinal chemistry 2025. link 2 Otani K, Watanabe T, Shimada S, Takeda S, Itani S, Higashimori A et al.. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Scientific reports 2016. link 3 Handy RL, Wallace P, Gaffen ZA, Whitehead KJ, Moore PK. The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. British journal of pharmacology 1995. link 4 Lin Q, Hu Y, Chen X, Cai X, Wang S. pH-responsive conformational variations regulate the emulsifying properties of Coprinus comatus protein-polysaccharide complex. Food research international (Ottawa, Ont.) 2026. link 5 Chen S, Yang J, Wang X, Liu X, Li X, Ye Y et al.. Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity. European journal of medicinal chemistry 2025. link 6 Farag M, Guedeney N, Schwalen F, Zadoroznyj A, Barczyk A, Giret M et al.. Towards New Anti-Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP-BIR2. ChemMedChem 2025. link 7 Lipinski MJ, Frias JC. Molecule 16673-34-0: a new tool in our arsenal against inflammation. Journal of cardiovascular pharmacology 2014. link 8 Sung MJ, Davaatseren M, Kim SH, Kim MJ, Hwang JT. Boehmeria nivea attenuates LPS-induced inflammatory markers by inhibiting p38 and JNK phosphorylations in RAW264.7 macrophages. Pharmaceutical biology 2013. link 9 Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G et al.. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007. link 10 García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL et al.. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. The Journal of biological chemistry 2001. link

TRIM22-related inflammatory bowel disease

Overview

Pathophysiology

Epidemiology

Clinical Presentation

Diagnosis

Differential Diagnosis

Management

First-Line Treatment

Second-Line Treatment

Refractory or Specialist Escalation

Complications

Prognosis & Follow-Up

Special Populations

Pediatric Patients

Elderly Patients

Comorbidities

Key Recommendations

References

Original source